Company Name, Ticker, Industry, else..

Valuation Comparisons

Management Effectiveness

Financial Strength

• Quick Ratio

• Working Capital

• LT Debt to Equity

• Debt to Equity

• Leverage Ratio

• Tangible Leverage

• Interest Coverage

• Debt Coverage

• Work. Cap. Per Revenue

Dividend Comparisons

Syros Pharmaceuticals Inc (SYRS)

Other Ticker:

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Syros Pharmaceuticals Inc 's Long Term Debt to Equity

SYRS's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth

Select the Comparisons :

None ▼

Select the Ratio:

Long Term Debt to Equity ▼

None ▼

Long Term Debt to Equity ▼

SYRS Long Term Debt to Equity	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Equity Change	49.89 %	21.79 %	-76.14 %	-58.14 %	-5.89 %
Y / Y Long Term Debt Change	0.97 %	1.1 %	-14.85 %	-2.37 %	1.79 %
Long Term Debt to Equity MRQ	0.32	0.31	1.1	0.62	0.47
Overall Ranking	# 860	# 1027	# 0	# 0	# 1049
Seq. Equity Change	-1.11 %	316.43 %	-50.56 %	-26.37 %	-19.65 %
Seq. Long Term Debt Change	0.33 %	19.27 %	-12.4 %	-3.68 %	0.46 %

New: More SYRS's historic Long Term Debt to Equity Ratios >>

Comment on SYRS Long Term Debt to Equity in the forth quarter 2022

Due to net new long-term borrowings of 0.33%, Long Term Debt to Equity fell to 0.32, above the Syros Pharmaceuticals Inc 's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 50 other companies have achieved lower Long Term Debt to Equity than Syros Pharmaceuticals Inc in the IV Quarter 2022. While Long Term Debt to Equity total ranking has improved so far in the forth quarter 2022 to 860, from total ranking in the third quarter 2022 at 1027.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt SYRS´s has?
What is the structure of SYRS´s Equity?

Long Term Debt to Equity forth quarter 2022 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 51
Healthcare Sector	# 131
Overall Market	# 860

Long Term Debt to Equity Statistics
High	Average	Low
1.1	0.26	0
(Jun 30 2022)		(Mar 31 2018)

Financial Statements
Syros Pharmaceuticals Inc 's Equity	$ 128 Millions	Visit SYRS's Balance sheet
Syros Pharmaceuticals Inc 's Long Term Debt	$ 41 Millions	Visit SYRS's Balance sheet
Source of SYRS's Sales		Visit SYRS's Sales by Geography

Cumulative Syros Pharmaceuticals Inc 's Long Term Debt to Equity

SYRS's Long Term Debt to Equity for the trailling 12 Months

SYRS Long Term Debt to Equity	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Equity TTM Growth	49.89 %	21.79 %	-76.14 %	-58.14 %	-5.89 %
Y / Y Long Term Debt TTM Growth	0.97 %	1.1 %	-14.85 %	-2.37 %	1.79 %
Long Term Debt to Equity TTM	0.44	0.5	0.54	0.41	0.34
Total Ranking TTM	# 811	#	#	#	#
Seq. Equity TTM Growth	-1.11 %	316.43 %	-50.56 %	-26.37 %	-19.65 %
Seq. Long Term Debt TTM Growth	0.33 %	19.27 %	-12.4 %	-3.68 %	0.46 %

SYRS Company Profile >> Back to SYRS Financial Strength Comparisons >> Compare SYRS Debt to Equity Ratio to its Competitors

TTM Long Term Debt to Equity Comment

On the trailing twelve months basis Despite of the net new long-term borrowings of 0.33% during the twelve months period ending in IV Quarter 2022 Syros Pharmaceuticals Inc has managed to decrease Long Term Debt to Equity in the IV Quarter 2022 to 0.44, a new company high.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 2, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Syros Pharmaceuticals Inc . While Long Term Debt to Equity total ranking has improved so far to 0, from total ranking in previous 12 month period at 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt SYRS´s has?
What is the structure of SYRS´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 10
Within the Market	# 47

TTM Long Term Debt to Equity Statistics
High	Average	Low
0.44	0.22	0
(Dec 31 2022)		(Dec 31 2017)

Companies with similar Long Term Debt to Equity in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry	Long Term Debt to Equity	Dec 31 2022 MRQ Long Term Debt	Dec 31 2022 MRQ Equity
Axsome Therapeutics Inc	0.86	$ 94.259 Millions	$ 109.556 Millions
Catalent Inc	0.86	$ 4,221.000 Millions	$ 4,912.000 Millions
Viatris Inc	0.85	$ 18,015.200 Millions	$ 21,072.300 Millions
Pacira Biosciences inc	0.85	$ 655.823 Millions	$ 775.010 Millions
Prestige Consumer Healthcare Inc	0.84	$ 1,424.095 Millions	$ 1,686.863 Millions
Perrigo Company Plc	0.84	$ 4,070.400 Millions	$ 4,842.100 Millions
Innoviva Inc	0.79	$ 444.180 Millions	$ 565.788 Millions
Vbi Vaccines Inc	0.76	$ 48.888 Millions	$ 64.163 Millions
Avid Bioservices Inc	0.76	$ 140.359 Millions	$ 185.395 Millions
Elanco Animal Health Inc	0.75	$ 5,448.000 Millions	$ 7,289.000 Millions
Cryoport inc	0.73	$ 407.063 Millions	$ 555.838 Millions
Cerevel Therapeutics Holdings Inc	0.64	$ 335.482 Millions	$ 521.238 Millions
Royalty Pharma Plc	0.64	$ 6,118.810 Millions	$ 9,525.373 Millions
Merck and Co Inc	0.62	$ 28,745.000 Millions	$ 46,058.000 Millions
Marinus Pharmaceuticals inc	0.61	$ 71.018 Millions	$ 116.000 Millions
Ironwood Pharmaceuticals inc	0.61	$ 396.251 Millions	$ 652.378 Millions
Maravai Lifesciences Holdings Inc	0.58	$ 521.997 Millions	$ 905.243 Millions
Tempest Therapeutics Inc	0.57	$ 10.371 Millions	$ 18.111 Millions
Corbus Pharmaceuticals Holdings Inc	0.57	$ 18.780 Millions	$ 32.990 Millions
Apellis Pharmaceuticals Inc	0.55	$ 92.736 Millions	$ 169.872 Millions
Verastem inc	0.52	$ 24.526 Millions	$ 47.391 Millions
Societal Cdmo Inc	0.52	$ 30.967 Millions	$ 59.859 Millions
Biovie Inc	0.51	$ 13.261 Millions	$ 26.068 Millions
Scpharmaceuticals Inc	0.51	$ 36.794 Millions	$ 72.433 Millions
Horizon Therapeutics Public Limited Company	0.50	$ 2,546.837 Millions	$ 5,072.174 Millions
Harmony Biosciences Holdings inc	0.47	$ 189.647 Millions	$ 402.838 Millions
Orgenesis Inc	0.46	$ 13.343 Millions	$ 29.071 Millions
Cumberland Pharmaceuticals Inc	0.45	$ 16.200 Millions	$ 35.974 Millions
Eton Pharmaceuticals Inc	0.41	$ 5.384 Millions	$ 13.078 Millions
Viracta Therapeutics Inc	0.41	$ 24.877 Millions	$ 61.103 Millions

Date modified: 2023-03-03T14:50:46+00:00


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar NVVE's Profile Stock Price NVVE's Financials Business Description Fundamentals Charts & Quotes NVVE's News Suppliers NVVE's Competitors Customers & Markets Economic Indicators NVVE's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Help

Sitemap

Advertise

About us

Glossary

Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071